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496Objectives:Hyperthermic chemotherapy perfusion has been used in the treatment of both pleural and peritoneal
mesothelioma without an extensive basic science foundation. Clinical data are limited with no prospective ran-
domized trials to support the use of this potentially toxic therapy. We sought to generate basic scientific support
for this clinical practice and to define the optimal conditions for use in future clinical trials.
Methods:Growth of a variety of invitro established cell lines, including a hyperthermia-sensitive Chinese hamster
ovary (CHO)-K1 cell line, a normal lung fibroblast line (MRC-5), a lung cancer line (A549), and 3 human meso-
thelioma cell lines (NCI-H28, NCI-H2052, and MSTO-211H), was assessed using a novel tetrazolium compound
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt [MTS])
and an electroncoupling reagent (phenazinemethosulfate),whichmeasures the absorbance at 490nmofa formazan
product reduced fromMTS by living cells (MTS metabolic assay), or a standard dilution clonogenic assay, which
enumerates colony-forming units of more than 50 cells. Each cell line was plated into flasks and then exposed to
varying combinations of chemotherapy agents and hyperthermia (37C-45C). The cells then were harvested
and assessed in either assay. The role of chemotherapeutic agents currently most commonly used in clinical prac-
tice, including cisplatin, gemcitabine, and pemetrexed, was assessed with and without simultaneous heat exposure.
Results: Conditions initially were explored using hyperthermia alone in CHO-K1, A549, and NCI-H28 cell
lines using temperatures of 37C, 42C, and 45C for 20, 40, and 60 minutes, respectively. This showed a repro-
ducible dose-response curve in CHO-K1 cells with increasing temperature producing lower survival to only
1.5% of the control at 45C for 60 minutes (P<.01). The A549 cells also showed a response but only at the
highest temperature, and the NCI-H28 cells showed a more modest reduction to 65% at 45C for 60 minutes
(P<.01). When the 2 assays were directly compared, the MTS assay failed to detect differences between groups
and therefore was discontinued from the remainder of these experiments. Next, hyperthermia was limited to the
physiologic limit of 42C, and the addition of chemotherapy was assessed. Doses were chosen on the basis of
prior pharmacokinetic data from studies showing a maximum tissue/blood level of 200 ng/mL for cisplatin pleu-
ral instillation and were thought to more accurately reflect actual tumor levels. Cisplatin alone modestly reduced
the clonogenic potential to 26%, 16.4%, and 13.6% at 42C, respectively, for 60 minutes (P<.01); however,
this was only a further reduction of 29.6%, 33.8%, and 34.2%, respectively, from the cisplatin alone control.
Therefore, most of the reduction was attributable to chemotherapy and not hyperthermia. With combinations
of cisplatin/gemcitabine and cisplatin/pemetrexed, the effect was larger, with reduction to 9.6%, 0%, and
0%, respectively (P<.01) (incremental reduction of 16.5%, 0%, and 0%, respectively, due to hyperthermia).
Cisplatin/pemetrexed produced essentially identical results.
Conclusions: Intrapleural chemotherapy seems to be most effective when using 2 drug combinations. All me-
sothelioma cell lines showed no particular sensitivity to heat. The use of hyperthermia alone or with chemother-
apy produces at best only a modest effect and does not necessarily support its current clinical use. (J Thorac
Cardiovasc Surg 2013;145:496-504)Malignant mesothelioma is one of only a few human tumors
that uniformly present as a diffuse primarymalignant process
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Abbreviations and Acronyms
CHO ¼ Chinese hamster ovary
MTS ¼ 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium,
inner salt
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tracavitary (intrapleural or intraperitoneal) administration, is
one such adjuvant therapy candidate. The treatment of cancer
by heat has a long history, and reports of hyperthermia and
mesothelioma date at least to the early 1970s.1 Woo and col-
leagues2 were the first to report a possible mesothelioma sen-
sitivity to hyperthermia in a fresh mesothelioma biopsy
specimen. Others have reported a selectivity of hyperthermia
for cancer cells in general.3 For decades, clinicians have eval-
uated hyperthermia in numerous clinical protocols,4-7 yet
level I/II data defining and supporting its role remain elusive.
Although there is a reasonable body of basic biology
research in the field of hyperthermia and cancer, relatively
little data exist specifically regarding malignant mesotheli-
oma. Mesothelioma, melanoma, and ovarian cancer are the
3 most common malignancies with a history of treatment
with hyperthermia. Although limb perfusion for melanoma
and intraperitoneal hyperthermic chemotherapy for ovarian
cancer have been somewhat systemically studied, the use of
hyperthermia in malignant mesothelioma has defied stan-
dardization. Variables in the clinical use of hyperthermia
for mesothelioma include (1) hyperthermic temperature,
ranging primarily from 41C to 43C (rarely higher); (2)
delivery method, which most often has used a cardiopulmo-
nary bypass perfusion circuit; (3) specific chemotherapy,
which has varied from doxorubicin to mitomycin, cytara-
bine, and bleomycin, and more recently to cisplatin, oxali-
platin, or even a combination of agents; and (4) exposure
time, which has been up to 120 minutes but most often
does not exceed 1 hour. Without detailed background infor-
mation on the optimal conditions to be incorporated in plan-
ning clinical trials, we decided to define the specific
parameters for the use of hyperthermia in the treatment of
mesothelioma by investigating the various factors in vitro.MATERIALS AND METHODS
Cell Lines
In vitro established cell lines, including a hyperthermia-sensitive Chi-
nese hamster ovary (CHO)-K1 cell line, a normal human lung fibroblast
line (MRC-5), a human lung cancer line (A549), and 3 human mesotheli-
oma cell lines (NCI-H28, NCI-H2052, and MSTO-211H), were obtained
from the American Type Culture Collection (Manassus, Va) and cultured
in 75 cm2 Vent Cap Greiner Tissue Culture Flasks (E&K Scientific, Santa
Clara, Calif). NCI-H28, NCI-H2052, and MSTO-211H were cultured in
Roswell Park Memorial Institute 1640; MRC-5 was cultured in Eagle’s
Minimum Essential Medium; and CHO-K1 was cultured in F12-K mediaThe Journal of Thoracic and Ca(American Type Culture Collection) supplemented with 10% fetal bovine
serum (Thermo Fisher Scientific, Pittsburgh, Pa) and antibiotics in a humid-
ified incubator at 37C with 5% CO2.
Hyperthermia
Cell lines were plated into 6-, 12-, or 96-well plates (Corning Inc, Tewks-
bury,Mass) at a density of approximately 13 105 cells/mL, depending on the
planned typeof assay, andallowed toadhere for 24hours before treatment. The
cells were treated during the exponential growth phase. After 24 hours, plates
were treated in water baths at 37C, 42C, or 45C for 0 to 60 minutes. After
treatment, the spent media were replaced with 3.0 mL of fresh media, and the
plates were cultured at 37C for an additional period of time before being
assessed by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) or clonogenic assay.
Chemotherapy
Chemotherapeutic agents commonly used with mesothelioma were cis-
platin (Sigma Aldrich, St Louis, Mo), which was diluted in dimethyl sulf-
oxide, and gemcitabine and pemetrexed (Eli Lilly, Indianapolis, Ind),
which were diluted in water.
All drugs were handled with personal protective equipment and diluted
in media to the desired concentrations for use in the experiments. After use,
all chemotherapy media and equipment were disposed in an approved bio-
hazard container.
MTS Assay
The MTS assay consists of a tetrazolium compound (MTS) and an elec-
tron coupling reagent (phenazine methosulfate). The assay measures met-
abolic activity as a surrogate for cell viability. For this assay, 1.0 3 104
cells/well were seeded into 96-well microplates (Corning Inc) and incu-
bated in a humidified incubator at 37C with 5% CO2 to allow cell attach-
ment. At the time of the assay, the spent media were replaced with 100 mL
of fresh media plus 20 mL MTS/phenazine methosulfate solution (Prom-
ega, Madison, Wis), and the plates were incubated for another 4 hours in
a humidified incubator at 37C with 5% CO2. The absorbance of formazan
reduced from MTS by metabolically active cells was measured at a wave-
length of 490 nm using the ELx80 microplate reader (BioTek Instruments,
Inc, Winooski, Vt). All assays were performed in triplicate, and the results
are expressed as a mean  standard error.
Clonogenic Assay
A standard clonogenic assay was performed to enumerate colony-
forming units of more than 50 cells. Cells from each cell line were placed
at a density of 100 to 500 cells/well in triplicate into 6-well plates (Corning
Inc) and incubated in a humidified incubator at 37C with 5% CO2 for 24
hours to allow the cells to adhere. After treatment with hyperthermia, the
spent media were replaced with 3.0 mL of fresh media at 37C and cultured
for 10 days in a humidified incubator at 37C with 5% CO2. Media were
removed, and the cells were washed with 13 phosphate-buffered solution
(Thermo Fisher Scientific). The colonies were fixed and stained with 2%
methyl blue (Sigma Aldrich) in methanol for 20 minutes. The plates
werewashed with water to remove the remainingmethyl blue and air dried.
Colonies containing 50 or more cells were counted. Plating efficiencies and
survival fractions were calculated from the ratio of the number of colonies
formed to the control numbers of cell plated. All assays were performed in
triplicate, and the results are expressed as a mean  standard error.
Statistical Analysis
Treatment group means  standard error were compared using Med-
Calc software version 12.2.1.0 (MedCalc Software bvba, Mariakerke,
Belgium), and t tests, assuming equal variance, were performed on groups
with significance levels calculated by a 2-tailed P value less than .001.rdiovascular Surgery c Volume 145, Number 2 497
FIGURE 1. Dose-response relationship for time and temperature. The response of CHO-K1, NCI-H28, and A549 cell lines to varying degrees of heat
(37C, 42C, and 45C) for varying time periods (0, 20, 40, and 60 minutes) is shown. The t test statistics are included where the results were statistically
significant compared with the no treatment control cultures at a P value less than .001. CHO, Chinese hamster ovary.
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Assay Selection
We initially evaluated and compared 2 different assays
designed to determine cell viability after in vitro exposure
to hyperthermia: an MTS metabolic assay and the more
traditional clonogenic assay. In numerous repeated
experiments, we exposed NCI-H28 and the known
hyperthermia-sensitive CHO-K1 cell lines to tempera-
tures of 37C, 42C, and 45C for 0, 20, 40, and 60 min-
utes, respectively. Each assay was then run in parallel
with both cell lines. The clonogenic assay consistently
demonstrated diminished cell viability as measured byFIGURE 2. Dose-response relationship for time at 42C for various cell line
MSTO-211H cell lines to varying time periods (0, 20, 40, and 60 minutes) at 4
tistically significant compared with the no treatment control cultures at a P val
498 The Journal of Thoracic and Cardiovascular Surgclonogenic potential after heat exposure, whereas the
MTS assay showed no detectable differences among the
experimental conditions (data not shown). The initial
MTS assays were performed 4 to 24 hours after hyper-
thermia treatment, but to be certain that our timing was
not an issue, we performed additional experiments with
MTS assay time points of 24, 48, 72, 96, 168, and 192
hours after heating. All failed to show any difference in
the MTS assay (data not shown). Thereafter for the re-
maining experiments reported in this article, we aban-
doned the use of MTS in favor of the more traditional
clonogenic assay.s. The response of CHO-K1, MRC-5, A549, NCI-H28, NCI-H2052, and
2C is shown. The t test statistics are included where the results were sta-
ue less than .001. CHO, Chinese hamster ovary.
ery c February 2013
FIGURE 3. Hyperthermic chemotherapy with cisplatin. The response of CHO-K1, MRC-5, A549, NCI-H28, NCI-H2052, and MSTO-211H cell lines to
varying doses of cisplatin chemotherapy combined with hyperthermia (42C) is shown. Of note, the reduction of cell viability mediated by chemotherapy
(variation between different shaded bars) was greater than that seen with hyperthermia (variation between similar shaded bars). Although almost all findings
were ‘‘statistically significant,’’ the differences would be clinically meaningless. CHO, Chinese hamster ovary.
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First we investigated the effect of both length of heat
exposure and exposure temperature on the survival of
CHO-K1, A549, and NCI-H28 cell lines. The results of
a representative experiment using temperatures of 37C,
42C, and 45C for 20, 40, and 60 minutes, respectively,
are shown in Figure 1. All cell lines showed a dose-
response to both temperature and time of hyperthermia
with the survival of cells reproducibly and progressively re-
duced to 1.5%  0.92%, 23.0%  2.87%, and 65.0% 
2.95% for the CHO-K1, A549, and mesothelioma NCI-
H28 cell lines, respectively (all P< .001). Although the
effect of hyperthermia alone was considerable for all cell
lines, the results were most consistent and greatest at
45C. Currently, clinical use of hyperthermia in mesotheli-
oma almost exclusively is limited to temperatures 43C or
less, with temperatures from 41C to 42C the most com-
mon. Therefore, we repeated these experiments concentrat-
ing on the clinically relevant temperature of 42C and tested
a wider range of cell lines, including 2 additional mesothe-
lioma cell lines: MSTO-211H and NCI-2072 (Figure 2). In
this experiment, the statistically significant (P<.001) but
perhaps clinically insignificant reduction in the survival of
CHO-K1 cells to 52.4%  3.95% was again seen along
with a reduction in the normal lung fibroblast cell lineThe Journal of Thoracic and CaMRC-5 to 65.8%  4.27% (P< .001). The remaining
cell lines, including all 3 mesothelioma cell lines, did not
have a statistically meaningful reduction in survival even
at the maximum time of 60 minutes at 42C.
Cell Line Sensitivity to Heat
We investigated the possibility that mesothelioma was
particularly sensitive to heat treatment, as previously re-
ported.2 In Figure 1, the NCI-H28 human mesothelioma
cell line was tested along with the A549 human lung cancer
line, and although both had statistically significant reduc-
tions in cell survival after 40 and 60 minutes at 45C, the
effect was more marked for the lung cancer cell line at
both times (P< .001). In Figure 2, all 3 mesothelioma
cell lines were heated for up to 60 minutes at 42C without
evidence of any effect despite the responsiveness of other
cell lines under the same conditions in the same assay,
such as the normal human lung fibroblast cell line MRC-
5, which showed statistically decreased survival to
68.5%  2.4% and 65.8%  4.3% at 40 and 60 minutes,
respectively (P<.001). There is no suggestion in either of
these 2 experiments that mesothelioma cell lines are partic-
ularly sensitive to hyperthermia when compared with other
cell types. If anything, the results suggest that they may be
more resistant.rdiovascular Surgery c Volume 145, Number 2 499
FIGURE 4. Hyperthermic chemotherapy with multiagent chemotherapy. The response of CHO-K1, MRC-5, A549, NCI-H28, NCI-H2052, and MSTO-
211H cell lines to varying doses of combination chemotherapy with cisplatin þ pemetrexed (A) or cisplatin þ gemcitabine (B), both with hyperthermia,
(42C) is shown. Of note, the reduction of cell viability mediated by chemotherapy (variation between different shaded bars) was greater than that seen with
hyperthermia (variation between similar shaded bars). Although almost all findings were ‘‘statistically significant,’’ the differences would be clinically
meaningless. CHO, Chinese hamster ovary.
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Hyperthermia
The combination of cisplatin and hyperthermia was
investigated by the addition of varying concentrations of
cisplatin (1, 2, and 4 mg/mL) as a single agent during heat ex-
posure. These specific concentrations were chosen on the ba-
sis of pharmacokinetic data from prior studies showing
a maximum blood/tissue level of approximately 200 ng/mL
for intrapleural cisplatin instillation.8 Our levels exceeded
the existing data by a factor of 50 and were thought to most
accurately reflect attainable tumor tissue levels in vivo. The
results (Figure 3) show a dose-response relationship for cis-
platin, with increasing cisplatin levels producing decreasing
cell survival. At maximum cisplatin concentration (100 mg/
mL), maximum temperature (42C), and maximum time
(60minutes), the clonogenic potential of the 3 mesothelioma
cell lines (NCI-H28, NCI-H2052, and MSTO-211H) was
modestly reduced to 26%, 16.4%, and 13.6%, respectively
(P<.01). The level of hyperthermia used in this experiment
is equivalent to that most commonly used in clinical practice,
but when the level was analyzed separately, a further reduc-
tion of only 29.6%, 33.8%, and 34.2%, respectively, was
produced from the use of cisplatin alone. Therefore, the
greatest proportion of the reduction in cell viability was
attributable to chemotherapy and not to hyperthermia.Combination Chemotherapy and Hyperthermia
The addition of combination chemotherapy to hyperther-
mia was investigated using 2 clinically active drug combi-
nations: cisplatin and pemetrexed (Figure 4, A), and
cisplatin and gemcitabine (Figure 4, B). With combinations
of cisplatin/gemcitabine and cisplatin/pemetrexed, the re-
duction in cellular viability was greater than with the
single-agent cisplatin alone. For the 3 mesothelioma cell
lines (NCI-H28, NCI-H2052, and MSTO-211H), cisplatin
and gemcitabine reduced cell survival to 9.6%, 0%, and
0%, respectively (P<.01), and cisplatin and pemetrexed re-
duced the clonogenic potential to 0%, 7.2%, and 4.5%,
respectively (P<.01). The contributions of hyperthermia
to the reduction in cellular viability among the 3 mesothe-
lioma cell lines, however, was only 16.5%, 0%, and 0%,
respectively, for the combination of cisplatin and gemcita-
bine and only 17.1%, 28.4%, and 22.8%, respectively,
for the combination of cisplatin and pemetrexed (Table 1).DISCUSSION
Hyperthermia with and without chemotherapy has been
proposed as an intraoperative adjunct to surgical resection,
whether lung-sparing pleurectomy or extra-pleural pneumo-
nectomy. Enthusiasm for this treatment approach, in part,
stems from the belief that tumors cell in general and
mesothelioma cells in particular are sensitive to the combi-
nation of heat and chemotherapy.2,9 Woo and colleagues2The Journal of Thoracic and Cadocumented a difference in heat sensitivity of various
tumors, with mesothelioma being the most sensitive. How-
ever, Woo and colleagues’ study used freshly harvested
tumor pieces and not established cell lines as in our studies.
Fresh tumors are not pure cell populations and include
a wide variety of contaminating cells, which can yield con-
flicting results. Furthermore, many fresh mesothelioma
tumors do not quickly or easily adapt to in vitro culture,
and when hyperthermia is added to the conditions during
the transition period, the resulting datamay incorrectly attri-
bute a general loss of cell viability to that specifically due to
hyperthermia. Although our data (Figures 1 and 2) do show
a temperature- and time-dependent reduction in cellular
viability, the mesothelioma cell lines demonstrate no partic-
ular sensitivity to hyperthermia and, in fact, seem more
resistant to the effects of heat when compared with A549,
a human lung cancer cell line, and MRC-5, a human lung
fibroblast cell line.
One incidental finding from our study was that the MTS
assay, which measures cellular metabolism, was unreliable
for measuring changes in cellular viability after hyperther-
mia treatment, particularly when compared with a tradi-
tional clonogenic assay. Possible explanations include
a neutralizing increase in metabolism due to the induction
of thermotolerance and ‘‘heat shock’’ metabolic activity
that balanced the opposing decrease in metabolic activity
due to diminished cellular viability. However, the true rea-
son for this finding remains unclear.
Despite the determined use of intraoperative hyperther-
mic chemotherapy at somemesothelioma treatment centers,
no true level I/II evidence exists to support its current use. It
is precisely this lack of definitive basic scientific and clini-
cal data that accounts for the considerable variations in
treatment details in clinical reports to date. For instance,
there is no consensus as to the temperature required or the
length of exposure time necessary for optimal effectiveness.
Perfusate temperatures vary primarily from 39C to 43C,
with many surgeons currently targeting a perfusate temper-
ature of 41.5C to 42C, often by simply using a cardiopul-
monary perfusion circuit and heat exchanger with limited
heating capabilities. Our data (Figures 1 and 2) are consis-
tent with previous basic hyperthermia research findings,
which suggest that temperature elevations limited to modest
levels (ie,<43C) are associated with a limited effective-
ness of hyperthermia compared with temperatures of
44C to 45C or higher.9 One likely factor at least partially
accounting for this observation is that cells heated to tem-
peratures less than 43C (compared with higher tempera-
tures) develop thermotolerance simultaneously with
heating,10,11 a phenomenon that explains the change in
the slope at 43C of the line depicting the energy required
for cellular inactivation versus temperature (Arrhenius
analysis) with temperatures less than 43C requiring
increased energy for cellular inactivation.12 Onerdiovascular Surgery c Volume 145, Number 2 501
TABLE 1. Specific proportional reduction in cell viability mediated by hyperthermia in multiagent hyperthermic chemotherapy
Cell line Time (min)
Pemetrexed (mg/mL)
Heat alone 0 0.1 1 10 100
MRC-5 20 18.48  4.65 9.14  4.58 4.19  3.57 12.76  4.05 27.05  2.06 33.71  1.14
40 36.57  6.01 25.90  2.87 45.52  4.93 43.24  2.01 40.19  3.75 39.24  0.66
60 52.76  1.19 52.00  2.31 51.05  2.16 47.24  1.19 46.67  2.31 44.38  1.19
A549 20 14.20  1.30 12.21  0.91 5.96  1.80 2.98  1.53 2.38  2.69 2.98  1.24
40 20.95  2.53 15.69  1.13 8.94  2.43 8.34  2.28 7.55  1.19 5.76  0.60
60 29.20  1.24 41.11  0.75 18.47  1.94 15.59  2.55 10.92  0.34 7.75  0.34
NCI-H28 20 9.76  3.37 6.34  6.92 11.71  4.39 8.29  2.24 6.34  2.24 12.20  1.46
40 14.15  3.05 18.05  5.14 14.63  4.39 20.98  5.07 20.98  2.24 31.68  0.01
60 17.07  3.05 20.49  3.87 25.37  5.14 36.59  2.24 31.22  1.69 31.68  0.01
NCI-H2052 20 8.70  2.03 21.48  3.46 17.39  2.69 20.97  2.69 16.62  4.36 20.46  1.93
40 20.20  5.03 36.83  1.60 29.67  1.93 30.18  4.23 24.55  3.19 25.58  2.34
60 28.39  2.47 41.18  2.03 37.85  1.60 36.32  2.47 29.67  1.93 29.67  1.17
MSTO-211H 20 11.26  1.74 6.21  2.11 3.91  2.42 10.57  3.16 5.52  1.05 8.62  0.49
40 19.08  3.26 15.17  3.11 20.00  4.04 25.98  1.74 10.34  1.05 11.72  0.98
60 22.76  4.52 20.00  2.87 24.14  2.79 43.22  1.05 15.17  1.05 12.76  0.49
This table quantifies the additional proportional reduction in cellular viability of CHO-K1, MRC-5, A549, NCI-H28, NCI-H2052, and MSTO-211H cell lines specifically
mediated by hyperthermia in varying combination chemotherapy conditions. Although many findings were ‘‘statistically significant,’’ the additional benefit of hyperthermia was
modest and observed primarily at the longer time intervals.
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of this thermotolerance involves upregulation of Hsp40/
Hsp70 expression at temperatures less than 43C.13
The issue of temperature is complicated further by the
general absence of tissue temperature as an end point in
clinical reports. Perfusate temperatures (inlet or outlet) as
surrogates for intrapleural temperatures almost invariably
are recorded and do not necessarily reflect the critical tissue
temperatures in the chest wall, mediastinum, and lung. Or-
gan/tissue temperatures, when reported, have been limited
to esophageal, rectal, and pulmonary artery temperatures,
which consistently are 39.5C or less,14 no higher than
a postoperative fever after talc pleurodesis.
The length of hyperthermia time also is fairly arbitrary,
ranging from 30 to 120 minutes in clinical reports. Our
data in Figure 1 show that increasing hyperthermia time
to 60 minutes decreases cell survival in all cell lines, includ-
ing the normal lung fibroblast cell line MRC-5. Together
with our temperature data, this suggests that the optimal
conditions for intraoperative hyperthermia would most
likely include exposure to at least 45C for 60 minutes or
more. However, the toxicity of these levels of hyperthermia
in vivo is unknown, and it may be strategically more suc-
cessful to use higher temperatures (ie, 45C-46C) (possi-
bly with newer perfusion circuits15) and shorter time
intervals (ie, 20-40 minutes). As shown in Figure 1, 45C
for 40 minutes produced superior results compared with
42C for 60 minutes in all cell lines.
Multiagent chemotherapy predictably is better than
monotherapy (Figure 4). Of note, any effectiveness of hy-
perthermia seemed to decrease with increasing chemother-
apy efficacy. In all cases, hyperthermia at clinically relevant
levels (ie, 42C for 60 minutes) only augmented the502 The Journal of Thoracic and Cardiovascular Surgeffectiveness of the multiagent platinum-based chemother-
apy combinations between 0% and 28.4%.
There are limitations to in vitro assays in determining the
effect of hyperthermia on cancer cells in vivo. For instance,
the treatment of cell monolayers does not necessarily pre-
dict results using 3-dimensional tumor/normal tissues and
intact vascularized solid tumor areas, in particular. Further-
more, hyperthermia-induced inflammatory cascades,
immune responses, and vascular permeability, as well as
other changes, are not present, cannot be measured, and
may be complicated or even overwhelmed by additional
changes in these parameters induced by the surgical proce-
dure itself. Yet, intraoperative hyperthermic perfusion opti-
mally is applied to minimal residual superficial disease,
which at least ostensibly, does somewhat resemble tissue
culture conditions.
Yet another issue regarding the effectiveness of intracavi-
tary hyperthermia is the well-documented ‘‘heat sink’’
effect of areas of large blood vessels/flow.16-19 With the
large blood flow through the mediastinum, lung, upper
extremity/thoracic outlet, and liver/spleen/organs below
the diaphragm, the ability of the chest cavity to act as
a radiator and dissipate heat can be a daunting challenge.
Despite measuring an inlet and outlet temperature of
42C, the effective temperature at the tissue level may be
far less, thereby further compromising the utility of
hyperthermia therapy. Few researchers document the
actual tissue temperature with temperature probes and
when done show only an extremely modest effect in the
esophagus and pulmonary blood of the lung (38.6C).20
Thus, the current clinical practice using perfusate tempera-
tures of 42C for 60 minutes clearly may not be optimal, but
the ideal hyperthermia time and temperature remain to beery c February 2013
Gemcitabine (nM/mL)
Heat alone 0 1 10 100 1000
13.36  3.61 8.90  2.59 3.77  3.14 16.78  1.57 1.71  4.86 7.88  2.59
36.99  4.63 31.16  5.84 19.86  3.71 26.03  3.14 19.52  4.71 8.22  1.03
47.60  3.70 50.68  3.14 32.19  3.71 35.62  3.08 26.37  1.57 14.73  1.57
14.23  2.14 15.09  1.74 16.22  1.48 7.40  1.24 4.17  2.96 7.69  1.43
22.39  2.42 18.69  1.35 22.77  1.58 15.46  2.42 11.01  2.56 9.11  1.28
28.08  3.12 37.29  1.90 34.16  1.48 25.05  1.24 18.88  0.72 10.53  2.10
7.89  0.74 5.03  1.81 25.84  1.63 11.83  1.20 3.75  0.74 6.21  1.18
11.14  2.46 14.60  1.36 32.15  1.97 20.02  2.52 15.38  2.07 8.28  0.78
13.41  2.10 25.44  1.04 40.73  0.95 28.40  2.52 24.06  1.90 16.47  1.63
8.65  2.98 16.54  4.56 7.14  3.26 2.26  6.21 3.01  4.92 <0.01  0.01
19.17  4.56 31.95  3.96 20.68  1.72 14.29  3.45 20.30  4.70 <0.01  0.01
22.93  2.84 36.47  3.63 22.93  2.84 18.80  1.72 24.44  2.98 <0.01  0.01
12.83  2.81 2.72  3.11 12.50  3.75 17.07  1.54 9.67  3.11 <0.01  0.01
18.26  3.61 11.09  2.62 22.07  1.82 23.91  1.54 18.04  1.23 <0.01  0.01
20.33  3.98 15.11  1.82 28.04  3.33 25.33  0.86 22.50  1.47 <0.01  0.01
TABLE 1. Continued
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spective randomized clinical trials.
The pleural space after complete pleurectomy or even ex-
trapleural pneumonectomy offers a huge absorptive surface
that produces systemic blood levels of chemotherapy agents
that are similar to those seen when similar doses are given
intravenously.8 Because of this massive absorptive surface,
the large differential concentrations of chemotherapy lo-
cally in the chest compared with blood/systemic levels are
not as great as in the peritoneum, where a greater proportion
of the mesothelial surface remains intact to prevent rapid
absorption of the instilled chemotherapy agents. This is par-
ticularly true when hyperthermia and chemotherapy are
combined.7 The large blood flow through the mediastinum
and lung also acts to efficiently absorb any drug(s) in the
chest and rapidly distribute them systemically.
The modest level of increased cytotoxicity mediated by
hyperthermia (Figures 3 and 4, A and B, and Table 1) would
most likely be clinically meaningless in the log-kill (Skip-
per–Schabel–Wilcox) model of cancer exponential growth
kinetics, which requires several ‘‘log kills’’ to even ap-
proach an effectiveness level that is clinically detectable
and meaningful.21,22
CONCLUSIONS
Our data demonstrate that hyperthermia and chemother-
apy have a dose response (temperature and time) as mea-
sured in mesothelioma cell lines, but the general
perception that mesothelioma is a heat-sensitive tumor is
not supported by our data. Further, the level of hyperthermia
required for clinically relevant cytotoxicity is likely to be
45C or greater. Other findings are that multiagent chemo-
therapy seems to have tremendous benefit over single-agentThe Journal of Thoracic and Catherapy and that the greater the effect of chemotherapy, the
smaller the apparent benefit of hyperthermia. Taken to-
gether, these data suggest that the current practice of pleural
perfusion at 42C for 1 hour often with single-agent cis-
platin is likely ineffective and that the optimal target for in-
traoperative hyperthermic chemotherapy perfusion would
use combinations of chemotherapy agents, such as cisplatin
and pemetrexed or cisplatin and gemcitabine, at 45C or
greater for 60 minutes or more, if tolerated on the basis of
clinical toxicity. Even with these data, randomized prospec-
tive clinical trials are warranted before any conclusions can
be made regarding the efficacy of this largely theoretic ap-
proach to cancer treatment in patients with mesothelioma.
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